Trade Summary

2 days ago, Krishnan Suma, serving as President, R&D at Krystal Biotech, Inc. (KRYS), sold 25,000 shares at $308.11 per share, for a total transaction value of $7,702,825.23. Following this transaction, Krishnan Suma now holds 1,378,155 shares of KRYS.

This sale represents a 1.78% decrease in Krishnan Suma's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, June 4, 2026 and publicly disclosed via SEC Form 4 filing on Friday, June 5, 2026 at 6:40 PM ET, 1 day after the trade was made.

Krystal Biotech, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.